Form 4: Harmony Biosciences CFO Sells Shares

Harmony Biosciences CFO Sandip Kapadia sold 21,573 shares of common stock for approximately $787,470 under a pre-arranged trading plan.

Summary

• Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported a sale of common stock.
• The transaction involved the disposition of 21,573 shares of common stock.
• The shares were sold on August 15, 2025, at a weighted average price of $36.4983 per share.
• The total value of the shares sold amounts to approximately $787,470.04.
• The sales were executed pursuant to a Rule 10b5-1 trading plan.
• Individual share prices for the sale ranged from $36.11 to $36.87.
• Following this transaction, the reporting person's direct beneficial ownership of these specific shares is 0.

Sentiment

Score: 5

Explanation: The filing reports an insider sale of common stock, which is a factual transaction. The sale was conducted under a Rule 10b5-1 trading plan, which indicates it was pre-scheduled and not necessarily based on new material non-public information, thus mitigating potential negative sentiment.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information, which enhances transparency.

Negatives

• The Chief Financial Officer sold a significant number of shares, reducing their direct beneficial ownership of these specific shares to zero.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, though the 10b5-1 plan suggests a pre-planned personal financial decision.

Key Dates

Recommendation

The filing reports a pre-scheduled sale of common stock by the Chief Financial Officer under a Rule 10b5-1 trading plan. This type of transaction is often for personal financial planning or diversification and does not necessarily reflect a change in the officer's outlook on the company's future performance. Without additional context such as the officer's remaining holdings, other insider activity, or new company-specific news, this single transaction does not provide sufficient grounds for a change in investment recommendation.

Keywords

Harmony Biosciences, HRMY, Sandip Kapadia, CFO, Insider Sale, Stock Transaction, Form 4, 10b5-1 Plan